These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11209988)

  • 21. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
    Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
    J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
    Goicoechea M; de Vinuesa SG; Lahera V; Cachofeiro V; Gómez-Campderá F; Vega A; Abad S; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S231-5. PubMed ID: 17130267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated.
    Kaul S; Zadeh AA; Shah PK
    J Am Coll Cardiol; 2006 Sep; 48(5):914-23. PubMed ID: 16949480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy.
    Sartori MT; Rigotti P; Marchini F; Spiezia L; Baldan N; Furian L; Varvarikis C; Girolami A
    Transplantation; 2003 Apr; 75(7):994-8. PubMed ID: 12698086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism.
    Prins MH; Hirsh J
    Arch Intern Med; 1991 Sep; 151(9):1721-31. PubMed ID: 1888237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibrinolytic risk factor clustering and insulin resistance in healthy male relatives of men with intermittent claudication.
    Parry DJ; Grant PJ; Scott DJ
    Br J Surg; 2006 Mar; 93(3):315-24. PubMed ID: 16498597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.
    Speidl WS; Nikfardjam M; Niessner A; Zeiner A; Jordanova N; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
    Thromb Res; 2007; 119(3):331-6. PubMed ID: 16616324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system.
    Danese S; Papa A
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):826-8. PubMed ID: 18794594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of PAI-1 in cardiovascular pathology.
    Alessi MC; Juhan-Vague I
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):673-8. PubMed ID: 15283042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia.
    Sucak GT; Acar K; Sucak A; Kirazli S; Haznedar R
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):347-52. PubMed ID: 16788310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visceral fat as a determinant of fibrinolysis and hemostasis.
    Mertens I; Van Gaal LF
    Semin Vasc Med; 2005 Feb; 5(1):48-55. PubMed ID: 15968580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombosis and cardiovascular risk in the elderly.
    Tracy RP; Bovill EG
    Arch Pathol Lab Med; 1992 Dec; 116(12):1307-12. PubMed ID: 1456876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lipoprotein (a)--a mysterious factor in atherogenesis].
    Jelaković B; Laganović M; Kuzmanić D
    Lijec Vjesn; 2002; 124(11-12):366-71. PubMed ID: 12679978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human gender differences in fibrinolytic responses to exercise training and their determinants.
    Kulaputana O; Macko RF; Ghiu I; Phares DA; Goldberg AP; Hagberg JM
    Exp Physiol; 2005 Nov; 90(6):881-7. PubMed ID: 16118237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
    Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
    Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease.
    Panahloo A; Yudkin JS
    J Cardiovasc Risk; 1997 Apr; 4(2):91-9. PubMed ID: 9304490
    [No Abstract]   [Full Text] [Related]  

  • 39. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
    Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
    Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
    Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.